<DOC>
	<DOCNO>NCT00889837</DOCNO>
	<brief_summary>The purpose study assess pulmonary safety 2 dos Staccato Loxapine within day patient COPD .</brief_summary>
	<brief_title>Staccato Loxapine Pulmonary Safety Patients With COPD</brief_title>
	<detailed_description>To address possibility inhalation loxapine may adverse pulmonary effect , study two 10-mg inhaled dos loxapine placebo give 10 hr apart subject chronic obstructive pulmonary disease ( COPD ) . The objective determine time course reversibility pulmonary effect inhale loxapine compare placebo .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<criteria>History COPD least 6 month prebronchodilator FEV1 â‰¥40 % predict value &gt; 15 packyear history cigarette smoking . History asthma , acute chronic pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Staccato Loxapine</keyword>
	<keyword>COPD</keyword>
	<keyword>pulmonary safety</keyword>
</DOC>